INVOKANA® tablets, for oral use

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use INVOKANA® safely and effectively. See full prescribing information for INVOKANA.

INVOKANA (canagliflozin) tablets, for oral use
Initial U.S. Approval: 2013

------------------------ RECENT MAJOR CHANGES ------------------------
Dosage and Administration (2.2) 05/2016
Contraindications (4) 03/2016
Warnings and Precautions (5) 07/2016

-------------------------- INDICATIONS AND USAGE --------------------------

INVOKANA is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)

Limitation of Use:
• Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis (1)

------------------------ DOSAGE AND ADMINISTRATION ------------------------

• The recommended starting dose is 100 mg once daily, taken before the first meal of the day (2.1)
• Dose can be increased to 300 mg once daily in patients tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and require additional glycemic control (2.1)
• Assess renal function before initiating and periodically thereafter. Before initiating INVOKANA, consider risk factors for ketoacidosis. Patients on INVOKANA may require monitoring and temporary discontinuation of therapy in clinical situations known to predispose to ketoacidosis (5.2)
• Acute kidney injury and impairment in renal function: Consider temporarily discontinuing in settings of reduced oral intake or fluid losses. If acute kidney injury occurs, discontinue and promptly treat. Monitor renal function during therapy (5.3)
• Hyperkalemia: Monitor potassium levels in patients with impaired renal function and in patients predisposed to hyperkalemia (2.2, 5.4, 6.1, 8.6)
• Urosepsis and Pyelonephritis: Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated (5.5)
• Hypoglycemia: Consider a lower dose of insulin or the insulin secretagogue to reduce the risk of hypoglycemia when used in combination with INVOKANA (5.6)
• Genital mycotic infections: Monitor and treat if indicated (5.7)
• Hypersensitivity reactions: Discontinue INVOKANA and monitor until signs and symptoms resolve (5.8)
• Bone fracture: Consider factors that contribute to fracture risk before initiating INVOKANA (5.9)
• Increased LDL-C: Monitor LDL-C and treat if appropriate (5.10)

-------------------------- USE IN SPECIFIC POPULATIONS --------------------------

Most common adverse reactions associated with INVOKANA (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

-------------------------- DRUG INTERACTIONS --------------------------

• UGT inducers (e.g., rifampin): Canagliflozin exposure is reduced. Consider increasing dose from 100 mg to 300 mg (2.3, 7.1)
• Digoxin: Monitor digoxin levels (7.2)
• UGT Enzyme Inducers
• Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers

-------------------------- USE IN SPECIFIC POPULATIONS --------------------------

• Pregnancy: Advise females of the potential risk to a fetus especially during the second and third trimesters. (8.1)
• Lactation: INVOKANA is not recommended when breastfeeding (8.2)
• Geriatrics: Higher incidence of adverse reactions related to reduced intravascular volume (5.1, 8.5)
• Renal impairment: Higher incidence of adverse reactions related to reduced intravascular volume and renal function (2.2, 5.3, 8.6)
• Hepatic impairment: Not recommended with severe hepatic impairment (8.7)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 02/2017
INVOKANA® (canagliflozin) tablets

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14)].

Limitation of Use

INVOKANA® is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended starting dose of INVOKANA (canagliflozin) is 100 mg once daily, taken before the first meal of the day. In patients tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and require additional glycemic control, the dose can be increased to 300 mg once daily [see Warnings and Precautions (5.3), Clinical Pharmacology (12.2), and Patient Counseling Information (17)].

In patients with volume depletion, correcting this condition prior to initiation of INVOKANA is recommended [see Warnings and Precautions (5.1), Use in Specific Populations (8.5 and 8.6), and Patient Counseling Information (17)].

2.2 Patients with Renal Impairment

Assessment of renal function is recommended prior to initiation of INVOKANA and periodically thereafter.

The dose of INVOKANA is limited to 100 mg once daily in patients with moderate renal impairment with an eGFR of 45 to less than 60 mL/min/1.73 m².

Initiation of INVOKANA is not recommended in patients with an eGFR less than 30 mL/min/1.73 m².

Use of INVOKANA is not recommended when eGFR is persistently less than 45 mL/min/1.73 m² [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)].

INVOKANA is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² [see Contraindications (4)].

2.3 Concomitant Use with UDP-Glucuronosyl Transferase (UGT) Enzyme Inducers

If an inducer of UGTs (e.g., rifampin, phenytoin, phenobarbital, rifavirin) is co-administered with INVOKANA, consider increasing the dosage to 300 mg once daily in patients currently tolerating INVOKANA 100 mg once daily who have an eGFR of 60 mL/min/1.73 m² or greater and require additional glycemic control [see Drug Interactions (7.1)].

Consider another antihyperglycemic agent in patients with an eGFR of 45 to less than 60 mL/min/1.73 m² receiving concurrent therapy with a UGT inducer.

3 DOSAGE FORMS AND STRENGTHS

• INVOKANA 100 mg tablets are yellow, capsule-shaped, film-coated tablets with “CFZ” on one side and “100” on the other side.

• INVOKANA 300 mg tablets are white, capsule-shaped, film-coated tablets with “CFZ” on one side and “300” on the other side.

4 CONTRAINDICATIONS

• History of a serious hypersensitivity reaction to INVOKANA, such as anaphylaxis or angioedema [see Warnings and Precautions (5.8) and Adverse Reactions (6.1, 6.2)].

• Severe renal impairment (eGFR less than 30 mL/min/1.73 m²), end stage renal disease (ESRD), or patients on dialysis [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6)].

5 WARNINGS AND PRECAUTIONS

5.1 Hypotension

INVOKANA causes intravascular volume contraction. Symptomatic hypotension can occur after initiating INVOKANA [see Adverse Reactions (6.1)] particularly in patients with impaired renal function (eGFR less than 60 mL/min/1.73 m²), elderly patients, patients on either diuretics or medications that interfere with the renin-angiotensin-aldosterone system (e.g., angiotensin-converting-enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs]), or patients with low systolic blood pressure. Before initiating INVOKANA in patients with one or more of these characteristics, volume status should be assessed and corrected. Monitor for signs and symptoms after initiating therapy.

5.2 Ketoacidosis

Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including INVOKANA. Fatal cases of ketoacidosis have been reported in patients taking INVOKANA. INVOKANA is not indicated for the treatment of patients with type 1 diabetes mellitus [see Indications and Usage (1)].

Patients treated with INVOKANA who present with signs and symptoms consistent with severe metabolic acidosis should be assessed for ketoacidosis regardless of presenting blood glucose levels, as ketoacidosis may be present even if blood glucose levels are less than 250 mg/dL. If ketoacidosis is suspected, INVOKANA should be discontinued, patient should be evaluated, and prompt treatment should be initiated. Treatment of ketoacidosis may require insulin, fluid and carbohydrate replacement.

In many of the postmarketing reports, and particularly in patients with type 1 diabetes, the presence of ketoacidosis was not immediately recognized and institution of treatment was delayed because presenting blood glucose levels were below those typically expected for diabetic ketoacidosis (often less than 250 mg/dL). Signs and symptoms at presentation were consistent with dehydration and severe metabolic acidosis and included nausea, vomiting, abdominal pain, generalized malaise, and shortness of breath. In some but not all cases, factors predisposing to ketoacidosis such as insulin dose reduction, acute febrile illness, reduced caloric intake due to illness or surgery, pancreatic disorders suggesting insulin deficiency (e.g., type 1 diabetes, history of pancreatitis or pancreatic surgery), and alcohol abuse were identified.

Before initiating INVOKANA, consider factors in the patient history that may predispose to ketoacidosis including pancreatic insulin deficiency from any cause, caloric restriction, and alcohol abuse. In patients treated with INVOKANA consider monitoring for ketoacidosis and temporarily discontinuing INVOKANA in clinical situations known to predispose to ketoacidosis (e.g., prolonged fasting due to acute illness or surgery).

5.3 Acute Kidney Injury and Impairment in Renal Function

INVOKANA causes intravascular volume contraction [see Warnings and Precautions (5.1)] and can cause renal impairment [see Adverse Reactions (6.1)]. There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving INVOKANA; some required involved patients younger than 65 years of age.

Before initiating INVOKANA, consider factors that may predispose patients to acute kidney injury including hypovolemia, chronic renal insufficiency, congestive heart failure and concomitant medications (diuretics, ACE inhibitors, ARBs, NSAIDs). Consider temporarily discontinuing INVOKANA in any setting of reduced oral intake (such as acute illness or fasting) or fluid losses (such as gastrointestinal illness or excessive heat exposure); monitor patients for signs and symptoms of acute kidney injury. If acute kidney injury occurs, discontinue INVOKANA promptly and institute treatment.

INVOKANA increases serum creatinine and decreases eGFR. Patients with hypovolemia may be more susceptible to these changes. Renal function abnormalities can occur after initiating INVOKANA [see Adverse Reactions (6.1)]. Renal function should be evaluated prior to initiation of INVOKANA and monitored periodically thereafter. Dosage adjustment and more frequent renal function monitoring are recommended in patients with an eGFR below 60 mL/min/1.73 m². Use of INVOKANA is not recommended when eGFR is persistently less than 45 mL/min/1.73 m² and is contraindicated in patients with an eGFR less than 30 mL/min/1.73 m² [see Dosage and Administration (2.2), Contraindications (4) and Use in Specific Populations (8.6)].

5.4 Hyperkalemia

INVOKANA can lead to hyperkalemia. Patients with moderate renal impairment who are taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, or medications that interfere with the renin-angiotensin-aldosterone system are at an increased risk of developing hyperkalemia [see Dosage and Administration (2.2) and Adverse Reactions (6.1)].

Monitor serum potassium levels periodically after initiating INVOKANA in patients with impaired renal function and in patients predisposed to hyperkalemia due to medications or other medical conditions.

5.5 Uropepsis and Pyelonephritis

There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving SGLT2 inhibitors, including INVOKANA. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated [see Adverse Reactions (6.1)].

5.6 Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues

Insulin and insulin secretagogues are known to cause hypoglycemia. INVOKANA can increase the risk of hypoglycemia when combined with insulin or an insulin secretagogue [see Adverse Reactions (6.1)]. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with INVOKANA.

5.7 Genital Mycotic Infections

INVOKANA increases the risk of genital mycotic infections. Patients with a history of genital mycotic infections and uncircumcised males were more likely to develop genital mycotic infections [see Adverse Reactions (6.1)]. Monitor and treat appropriately.
INVOKANA® (canagliflozin) tablets

5.8 Hypersensitivity Reactions
Hypersensitivity reactions, including angioedema and anaphylaxis, have been reported with INVOKANA. These reactions generally occurred within hours to days after initiating INVOKANA. If hypersensitivity reactions occur, discontinue use of INVOKANA; treat and monitor until signs and symptoms resolve [see Contraindications (4) and Adverse Reactions (6.1, 6.2)].

5.9 Bone Fracture
An increased risk of bone fracture, occurring as early as 12 weeks after treatment initiation, was observed in patients using INVOKANA. Consider factors that contribute to fracture risk prior to initiating INVOKANA [see Adverse Reactions (6.1)].

5.10 Increases in Low-Density Lipoprotein (LDL-C)
Dose-related increases in LDL-C occur with INVOKANA [see Adverse Reactions (6.1)]. Monitor LDL-C and treat if appropriate after initiating INVOKANA.

5.11 Macrovascular Outcomes
There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with INVOKANA [see Adverse Reactions (6.1)].

6 ADVERSE REACTIONS
The following important adverse reactions are described below and elsewhere in the labeling:
- Hypotension [see Warnings and Precautions (5.1)]
- Ketoacidosis [see Warnings and Precautions (5.2)]
- Acute Kidney Injury and Impairment in Renal Function [see Warnings and Precautions (5.3)]
- Hyperkalemia [see Warnings and Precautions (5.4)]
- Urosepsis and Pyelonephritis [see Warnings and Precautions (5.5)]
- Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues [see Warnings and Precautions (5.6)]
- Genital Mycotic Infections [see Warnings and Precautions (5.7)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.8)]
- Bone Fracture [see Warnings and Precautions (5.9)]
- Increases in Low-Density Lipoprotein (LDL-C) [see Warnings and Precautions (5.10)]

6.1 Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Pool of Placebo-Controlled Trials
The data in Table 1 is derived from four 26-week placebo-controlled trials. In one trial INVOKANA was used as monotherapy and in three trials INVOKANA was used as add-on therapy [see Clinical Studies (14)]. These data reflect exposure of 1667 patients to INVOKANA and a mean duration of exposure to INVOKANA of 24 weeks. Patients received INVOKANA 100 mg (N=833), INVOKANA 300 mg (N=834) or placebo (N=848) once daily. The mean age of the population was 56 years and 2% were older than 75 years of age. Fifty percent (50%) of the population was male and 72% were Caucasian, 12% were Asian, and 5% were Black or African American. At baseline the population had diabetes for an average of 7.3 years, had a mean HbA1C of 8.0% and 33% had established microvascular complications of diabetes. Baseline renal function was normal or mildly impaired (mean eGFR 88 mL/min/1.73 m²). The types and frequency of common adverse reactions observed in the pool of eight clinical trials were consistent with those listed in Table 1. Percentages were weighted by studies. Study weights were proportional to the harmonic mean of the three treatment sample sizes. In this pool, INVOKANA was also associated with the adverse reactions of fatigue (1.8% with comparator, 2.2% with INVOKANA 100 mg, and 2.0% with INVOKANA 300 mg) and loss of strength or energy (i.e., asthenia) (0.6% with comparator, 0.7% with INVOKANA 100 mg, and 1.1% with INVOKANA 300 mg).

In the pool of eight clinical trials, the incidence rate of pancreatitis (acute or chronic) was 0.1%, 0.2%, and 0.1% receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. In the pool of eight clinical trials, hypersensitivity-related adverse reactions including erythema, rash, pruritus, urticaria, and angioedema occurred in 3.0%, 3.8%, and 4.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Five patients experienced serious adverse reactions of hypersensitivity with INVOKANA, which included 4 patients with urticaria and 1 patient with a diffuse rash and urticaria occurring within hours of exposure to INVOKANA. Among these patients, 2 patients discontinued INVOKANA. One patient with urticaria had recurrence when INVOKANA was re-initiated. Photosensitivity-related adverse reactions (including photosensitivity reaction, polymorphic light eruption, and sunburn) occurred in 0.1%, 0.2%, and 0.2% of patients receiving comparator, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.

Other adverse reactions occurring more frequently on INVOKANA than on comparator were:

Volume Depletion-Related Adverse Reactions
INVOKANA results in an osmotic diuresis, which may lead to reductions in intravascular volume. In clinical studies, treatment with INVOKANA was associated with a dose-dependent increase in the incidence of volume depletion-related adverse reactions (e.g., hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration). An increased incidence was observed in patients on the 300 mg dose. The three factors associated with the largest increase in volume depletion-related adverse reactions were the use of loop diuretics, moderate renal impairment (eGFR 30 to less than 60 mL/min/1.73 m²), and age 75 years and older (Table 2) [see Dosage and Administration (2.2), Warnings and Precautions (5.1), and Use in Specific Populations (8.5 and 8.6)].
INVOKANA® (canagliflozin) tablets

Table 2: Proportion of Patients With at Least One Volume Depletion-Related Adverse Reaction (Pooled Results from 8 Clinical Trials)

<table>
<thead>
<tr>
<th>Baseline Characteristic</th>
<th>Comparator Group* %</th>
<th>INVOKANA 100 mg %</th>
<th>INVOKANA 300 mg %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall population</td>
<td>1.5%</td>
<td>2.3%</td>
<td>3.4%</td>
</tr>
<tr>
<td>75 years of age and older1</td>
<td>2.6%</td>
<td>4.9%</td>
<td>8.7%</td>
</tr>
<tr>
<td>eGFR less than 60 mL/min/1.73 m²2</td>
<td>2.5%</td>
<td>4.7%</td>
<td>8.1%</td>
</tr>
<tr>
<td>Use of loop diuretic*</td>
<td>4.7%</td>
<td>3.2%</td>
<td>8.8%</td>
</tr>
</tbody>
</table>

* Includes placebo and active-comparator groups
1 Patients could have more than 1 of the listed risk factors
2 Some patients had more than 1 baseline eGFR measurement

Falls
In a trial carried out in patients with moderate renal impairment with a baseline eGFR of 30 to less than 50 mL/min/1.73 m² (mean baseline eGFR 48 mL/min/1.73 m²), the overall incidence of these events was lower than in the dedicated trial but a dose-dependent increase in incident episodes of significant renal function decline compared to placebo was still observed. Use of INVOKANA has been associated with an increased incidence of renal-related adverse reactions (e.g., increased blood creatinine, decreased glomerular filtration rate, renal impairment, and acute renal failure), particularly in patients with moderate renal impairment.

In the pooled analysis of patients with moderate renal impairment, the incidence of renal-related adverse reactions was 3.7% with placebo, 9.9% with INVOKANA 100 mg, and 9.3% with INVOKANA 300 mg. Discontinuations due to renal-related adverse events occurred in 1.0% with placebo, 1.2% with INVOKANA 100 mg, and 1.6% with INVOKANA 300 mg [see Warnings and Precautions (5.3)].

Genital Mycotic Infections
In the pool of four placebo-controlled clinical trials, female genital mycotic infections (e.g., vulvovaginal mycotic infection, vulvovaginal candidiasis, and vulvovaginitis) occurred in 2.8%, 10.6%, and 11.6% of females treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Patients with a history of genital mycotic infections were more likely to develop genital mycotic infections on INVOKANA. Female patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrence and require treatment with oral or topical antifungal agents and anti-microbial agents. In females, discontinuation due to genital mycotic infections occurred in 0% and 0.7% of patients treated with placebo and INVOKANA, respectively [see Warnings and Precautions (5.7)].

In the pool of four placebo-controlled clinical trials, male genital mycotic infections (e.g., balanitis, balanoposthitis) occurred in 0.7%, 4.2%, and 3.8% of males treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Male genital mycotic infections occurred more commonly in uncircumcised males and in males with a prior history of balanitis or balanoposthitis. Male patients who developed genital mycotic infections on INVOKANA were more likely to experience recurrent infections (22% on INVOKANA versus none on placebo), and require treatment with oral or topical antifungal agents and anti-microbial agents than patients on comparators. In males, discontinuations due to genital mycotic infections occurred in 0% and 0.5% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. In the pooled analysis of 8 controlled trials, phimosis was reported in 0.3% of uncircumcised male patients treated with INVOKANA and 0.2% required circumcision to treat the phimosis [see Warnings and Precautions (5.7)].

Hypoglycemia
In all clinical trials, hypoglycemia was defined as any event regardless of symptoms, where biochemical hypoglycemia was documented (any glucose value below or equal to 70 mg/dL). Severe hypoglycemia was defined as an event consistent with hypoglycemia where the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained). In individual clinical trials [see Clinical Studies (14)], episodes of hypoglycemia occurred at a higher rate when INVOKANA was co-administered with insulin or sulfonylureas (Table 4) [see Warnings and Precautions (5.6)].

Table 3: Changes in Serum Creatinine and eGFR Associated with INVOKANA in the Pool of Four Placebo-Controlled Trials and Moderate Renal Impairment Trial

<table>
<thead>
<tr>
<th>Pool of Four Placebo-Controlled Trials</th>
<th>Placebo N=646</th>
<th>INVOKANA 100 mg N=633</th>
<th>INVOKANA 300 mg N=834</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline Creatinine (mg/dL)</td>
<td>1.61</td>
<td>1.62</td>
<td>1.63</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²)</td>
<td>87.0</td>
<td>86.8</td>
<td>88.8</td>
</tr>
<tr>
<td>Week 6 Change Creatinine (mg/dL)</td>
<td>0.01</td>
<td>0.03</td>
<td>0.05</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²)</td>
<td>-1.6</td>
<td>-3.8</td>
<td>-5.0</td>
</tr>
<tr>
<td>End of Treatment Creatinine (mg/dL)</td>
<td>0.01</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td>eGFR (mL/min/1.73 m²)</td>
<td>-1.6</td>
<td>-2.3</td>
<td>-3.4</td>
</tr>
</tbody>
</table>

* Week 26 in mITT LOCF population

Table 4: Incidence of Hypoglycemia* in Controlled Clinical Studies

<table>
<thead>
<tr>
<th>Monotherapy (26 weeks)</th>
<th>Placebo (N=192)</th>
<th>INVOKANA 100 mg (N=195)</th>
<th>INVOKANA 300 mg (N=197)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall [N (%)]</td>
<td>5 (2.6)</td>
<td>7 (3.6)</td>
<td>7 (3.6)</td>
</tr>
<tr>
<td>In Combination with Metformin (26 weeks)</td>
<td>Placebo + Metformin (N=143)</td>
<td>INVOKANA 100 mg + Metformin (N=138)</td>
<td>INVOKANA 300 mg + Metformin (N=137)</td>
</tr>
<tr>
<td>Overall [N (%)]</td>
<td>155 (34.2)</td>
<td>20 (5.6)</td>
<td>27 (5.6)</td>
</tr>
<tr>
<td>Severe [N (%)]</td>
<td>3 (1.6)</td>
<td>1 (0.3)</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>In Combination with Metformin (52 weeks)</td>
<td>Placebo + Metformin (N=482)</td>
<td>INVOKANA 100 mg + Metformin (N=490)</td>
<td>INVOKANA 300 mg + Metformin (N=495)</td>
</tr>
<tr>
<td>Overall [N (%)]</td>
<td>15 (3.1)</td>
<td>2 (0.4)</td>
<td>3 (0.6)</td>
</tr>
<tr>
<td>Severe [N (%)]</td>
<td>1 (0.6)</td>
<td>1 (0.6)</td>
<td>0</td>
</tr>
<tr>
<td>In Combination with Sulfonylurea (18 weeks)</td>
<td>Placebo + Sulfonylurea (N=69)</td>
<td>INVOKANA 100 mg + Sulfonylurea (N=74)</td>
<td>INVOKANA 300 mg + Sulfonylurea (N=72)</td>
</tr>
<tr>
<td>Overall [N (%)]</td>
<td>4 (5.8)</td>
<td>3 (4.1)</td>
<td>9 (12.5)</td>
</tr>
<tr>
<td>In Combination with Metformin + Sulfonylurea (26 weeks)</td>
<td>Placebo + Metformin + Sulfonylurea (N=160)</td>
<td>INVOKANA 100 mg + Metformin + Sulfonylurea (N=163)</td>
<td>INVOKANA 300 mg + Metformin + Sulfonylurea (N=165)</td>
</tr>
<tr>
<td>Overall [N (%)]</td>
<td>24 (15.4)</td>
<td>43 (27.4)</td>
<td>47 (30.1)</td>
</tr>
<tr>
<td>Severe [N (%)]</td>
<td>1 (0.6)</td>
<td>1 (0.6)</td>
<td>0</td>
</tr>
<tr>
<td>In Combination with Metformin + Sulfonylurea (52 weeks)</td>
<td>Placebo + Metformin + Sulfonylurea (N=578)</td>
<td>INVOKANA 100 mg + Metformin + Sulfonylurea (N=578)</td>
<td>INVOKANA 300 mg + Metformin + Sulfonylurea (N=577)</td>
</tr>
<tr>
<td>Overall [N (%)]</td>
<td>154 (40.7)</td>
<td>163 (43.2)</td>
<td>16 (40.7)</td>
</tr>
<tr>
<td>Severe [N (%)]</td>
<td>13 (3.4)</td>
<td>15 (4.0)</td>
<td>0</td>
</tr>
</tbody>
</table>
### Table 4: Incidence of Hypoglycemia* in Controlled Clinical Studies (continued)

<table>
<thead>
<tr>
<th>In Combination with Metformin + Pioglitazone (26 weeks)</th>
<th>Placebo + Metformin + Pioglitazone (N=115)</th>
<th>INVOKANA 100 mg + Metformin + Pioglitazone (N=113)</th>
<th>INVOKANA 300 mg + Metformin + Pioglitazone (N=114)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall (N [%])</strong></td>
<td>3 (2.6)</td>
<td>3 (2.7)</td>
<td>6 (5.3)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>In Combination with Insulin (18 weeks)</th>
<th>Placebo (N=565)</th>
<th>INVOKANA 100 mg (N=566)</th>
<th>INVOKANA 300 mg (N=587)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Overall (N [%])</strong></td>
<td>208 (36.8)</td>
<td>279 (49.3)</td>
<td>285 (48.6)</td>
</tr>
<tr>
<td><strong>Severe (N [%])</strong></td>
<td>14 (2.5)</td>
<td>10 (1.8)</td>
<td>16 (2.7)</td>
</tr>
</tbody>
</table>

* Number of patients experiencing at least one event of hypoglycemia based on either biochemically documented episodes or severe hypoglycemic events in the intent-to-treat population.

† Severe episodes of hypoglycemia were defined as those where the patient required the assistance of another person to recover, lost consciousness, or experienced a seizure (regardless of whether biochemical documentation of a low glucose value was obtained).

### Bone Fracture

The occurrence of bone fractures was evaluated in a pool of nine clinical trials with a mean duration of exposure to INVOKANA of 85 weeks. The incidence rates of adjudicated bone fractures were 1.1, 1.4, and 1.5 per 100 patient-years of exposure in the comparator, INVOKANA 100 mg, and INVOKANA 300 mg groups, respectively. Fractures were observed as early as 12 weeks after treatment initiation and were more likely to be low trauma (e.g., fall from no more than standing height), and affect the upper extremities [see Warnings and Precautions (5.9)].

### Laboratory and Imaging Tests

**Increases in Serum Potassium**

In a pooled population of patients (N=722) with moderate renal impairment (eGFR 45 to less than 60 mL/min/1.73 m²), increases in serum potassium to greater than 5.4 mEq/L and 15% above baseline occurred in 5.3%, 5.0%, and 5.2% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. Severe elevations (greater than or equal to 6.5 mEq/L) occurred in 0.4% of patients treated with placebo, no patients treated with INVOKANA 100 mg, and 1.3% of patients treated with INVOKANA 300 mg. In these patients, increases in potassium were more commonly seen in those with elevated potassium at baseline. Among patients with moderate renal impairment, approximately 84% were taking medications that interfere with potassium excretion, such as potassium-sparing diuretics, angiotensin-converting enzyme inhibitors, and angiotensin-receptor blockers [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)].

**Increases in Serum Magnesium**

Dose-related increases in serum magnesium were observed early after initiation of INVOKANA (within 6 weeks) and remained elevated throughout treatment. In the pool of four placebo-controlled trials, the mean percent change in serum magnesium levels was 8.1% and 9.3% with INVOKANA 100 mg and INVOKANA 300 mg, respectively. Severe elevations occurred in 0.4% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively. In a trial of patients with moderate renal impairment [see Clinical Studies (14.3)], serum magnesium levels increased by 0.2%, 2.2%, and 14.6% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.

**Increases in Serum Phosphate**

Dose-related increases in serum phosphate levels were observed with INVOKANA. In the pool of four placebo controlled trials, the mean percent change in serum phosphate levels were 3.6% and 5.1% with INVOKANA 100 mg and INVOKANA 300 mg, respectively, compared to 0.6% with placebo. In a trial of patients with moderate renal impairment [see Clinical Studies (14.3)], serum phosphate levels increased by 1.2%, 5.0%, and 9.3% with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively.

**Increases in Low-Density Lipoprotein Cholesterol (LDL-C) and non-High-Density Lipoprotein Cholesterol (non-HDL-C)**

In the pool of four placebo-controlled trials, dose-related increases in LDL-C with INVOKANA were observed. Mean changes (percent changes) from baseline in LDL-C relative to placebo were 4.4 mg/dL (4.5%) and 8.2 mg/dL (8.0%) with INVOKANA 100 mg and INVOKANA 300 mg, respectively. The mean baseline LDL-C levels were 104 to 110 mg/dL across treatment groups [see Warnings and Precautions (5.10)].

Dose-related increases in non-HDL-C with INVOKANA were observed. Mean changes (percent changes) from baseline in non-HDL-C relative to placebo were 2.1 mg/dL (1.5%) and 5.1 mg/dL (3.6%) with INVOKANA 100 mg and 300 mg, respectively. The mean baseline non-HDL-C levels were 140 to 147 mg/dL across treatment groups.

### Increases in Hemoglobin

In the pool of four placebo-controlled trials, mean changes (percent changes) from baseline in hemoglobin were -0.18 g/dL (-1.1%) with placebo, 0.47 g/dL (3.5%) with INVOKANA 100 mg, and 0.51 g/dL (3.8%) with INVOKANA 300 mg. The mean baseline hemoglobin value was approximately 14.1 g/dL across treatment groups. At the end of treatment, 0.6%, 4.0%, and 2.7% of patients treated with placebo, INVOKANA 100 mg, and INVOKANA 300 mg, respectively, had hemoglobin above the upper limit of normal.

### Decreases in Bone Mineral Density

Bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry in a clinical trial of 714 older adults (mean age 64 years) [see Clinical Studies (14.3)]. At 2 years, patients randomized to INVOKANA 100 mg had a 4.6% (1.6%) decrease in BMD at the total hip of 0.9% and 1.2%, respectively, and at the lumbar spine of 0.3% and 0.7%, respectively. Additionally, placebo-adjusted BMD declines were 0.1% at the femoral neck for both INVOKANA doses and 0.4% at the distal forearm for patients randomized to INVOKANA 300 mg. The placebo-adjusted change at the distal forearm for patients randomized to INVOKANA 100 mg was 0%.

### 6.2 Postmarketing Experience

Additional adverse reactions have been identified during postapproval use of INVOKANA. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
INVOKANA® (canagliflozin) tablets

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:

The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a HbA1c >7 and has been reported to be as high as 20-25% in women with a HbA1c >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Clinical Considerations

Disease-associated maternal and/or embryo/fetal risk

Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, stillbirth and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.

Animal Data

Canagliflozin, the active ingredient of INVOKANA, is chemically known as (1S)-1,5-anhydro-1-[[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol hemihydrate and has the molecular formula and weight of C24H25FO5S•1/2 H2O and 453.53, respectively. The structural formula for canagliflozin is:
12.2 Pharmacodynamics

Following single and multiple oral doses of canagliflozin in patients with type 2 diabetes, dose-dependent decreases in the renal threshold for glucose (RTG) and increases in urinary glucose excretion were observed. From a starting RTG value of approximately 240 mg/dL, canagliflozin at 100 mg and 300 mg once daily suppressed RTG throughout the 24-hour period. Maximal suppression of mean RTG over the 24-hour period was seen with the 300 mg daily dose to approximately 70 to 90 mg/dL in patients with type 2 diabetes in Phase 1 studies. The reductions in RTG led to increases in mean UGE of approximately 100 g/day in subjects with type 2 diabetes treated with either 100 mg or 300 mg of canagliflozin. In patients with type 2 diabetes given 100 mg to 300 mg once daily over a 16-day dosing period, reductions in RTG and increases in urinary glucose excretion were observed over the dosing period. In this study, plasma glucose declined in a dose-dependent fashion within the first day of dosing. In single-dose studies in healthy and type 2 diabetic subjects, treatment with canagliflozin 300 mg before a mixed-meal delayed intestinal glucose absorption and reduced postprandial glucose.

Cardiac Electrophysiology

In a randomized, double-blind, placebo-controlled, active-comparator, 4-way crossover study, 60 healthy subjects were administered a single oral dose of canagliflozin 300 mg, canagliflozin 1,200 mg (4 times the maximum recommended dose), moxifloxacin, and placebo. No meaningful changes in QTc interval were observed with either the recommended dose of 300 mg or the 1,200 mg dose.

12.3 Pharmacokinetics

The pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Following single-dose oral administration of 100 mg and 300 mg of INVOKANA, peak plasma concentrations (median T_{max}) of canagliflozin occurs within 1 to 2 hours post-dose. Plasma C_{max} and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. The apparent terminal half-life (t_{1/2}) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively. Steady-state was reached after 4 to 5 days of once-daily dosing with canagliflozin 100 mg to 300 mg. Canagliflozin does not exhibit time-dependent pharmacokinetics and accumulated in plasma up to 26% following multiple doses of 100 mg and 300 mg.

Absorption

The mean absolute oral bioavailability of canagliflozin is approximately 85%. Co-administration of a high-fat meal with canagliflozin had no effect on the pharmacokinetics of canagliflozin; therefore, INVOKANA may be taken with or without food. However, based on the potential to reduce postprandial plasma glucose excursions due to delayed intestinal glucose absorption, it is recommended that INVOKANA be taken before the first meal of the day (see Dosage and Administration (2.1)).

Distribution

The mean steady-state volume of distribution of canagliflozin following a single intravenous infusion in healthy subjects was 53.5 L, suggesting extensive tissue distribution. Canagliflozin is extensively bound to proteins in plasma (99%), mainly to albumin. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.

Metabolism

O-glucuronidation is the major metabolic elimination pathway for canagliflozin, which is mainly glucuronidated by UGT1A9 and UGT2B4 to two inactive O-glucuronide metabolites.

CYP3A4-mediated (oxidative) metabolism of canagliflozin is minimal (approximately 7%) in humans.

Excretion

Following administration of a single oral [14C] canagliflozin dose to healthy subjects, 41.5%, 7.0%, and 3.2% of the administered radioactive dose was recovered in feces as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively. Enterohepatic circulation of canagliflozin was negligible.

Approximately 33% of the administered radioactive dose was excreted in urine, mainly as O-glucuronide metabolites (30.5%). Less than 1% of the dose was excreted as unchanged canagliflozin in urine. Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

Mean systemic clearance of canagliflozin was approximately 192 mL/min in healthy subjects following intravenous administration.

Specific Populations

Renal Impairment

A single-dose, open-label study evaluated the pharmacokinetics of canagliflozin 200 mg in patients with varying degrees of renal impairment (classified using the MDRD-eGFR formula) compared to healthy subjects.
INVOKANA® (canagliflozin) tablets

Table 6: Effect of Canagliflozin on Systemic Exposure of Co-Administered Drugs

<table>
<thead>
<tr>
<th>Co-Administered Drug</th>
<th>Dose of Co-Administered Drug†</th>
<th>Dose of Canagliflozin*</th>
<th>Geometric Mean Ratio (Ratio With/Without Co-Administered Drug)</th>
<th>No Effect = 1.0</th>
<th>AUC* (90% CI)</th>
<th>Cmax (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>1,000 mg</td>
<td>300 mg BID for 25 days</td>
<td>acetaminophen</td>
<td></td>
<td>1.00 (0.99; 1.01)</td>
<td></td>
</tr>
<tr>
<td>Ethinyl estradiol</td>
<td>0.03 mg estradiol and 0.15 mg levonorgestrel</td>
<td>200 mg QD for 6 days</td>
<td>ethinyl estradiol</td>
<td></td>
<td>1.10 (1.09; 1.11)</td>
<td></td>
</tr>
<tr>
<td>Glyburide</td>
<td>1.25 mg</td>
<td>200 mg QD for 6 days</td>
<td>glyburide</td>
<td></td>
<td>0.96 (0.95; 0.98)</td>
<td></td>
</tr>
<tr>
<td>Hydrochlorothiazide</td>
<td>25 mg QD for 35 days</td>
<td>300 mg QD for 35 days</td>
<td>hydrochlorothiazide</td>
<td></td>
<td>0.96 (0.95; 0.98)</td>
<td></td>
</tr>
<tr>
<td>Metformin</td>
<td>2,000 mg</td>
<td>300 mg QD for 8 days</td>
<td>metformin</td>
<td></td>
<td>0.97 (0.96; 0.98)</td>
<td></td>
</tr>
<tr>
<td>Simvastatin</td>
<td>40 mg</td>
<td>300 mg QD for 7 days</td>
<td>simvastatin</td>
<td></td>
<td>1.03 (1.02; 1.05)</td>
<td></td>
</tr>
<tr>
<td>Warfarin</td>
<td>30 mg</td>
<td>300 mg QD for 12 days</td>
<td>(S)-warfarin</td>
<td></td>
<td>1.00 (0.99; 1.01)</td>
<td></td>
</tr>
</tbody>
</table>

No dose adjustments of co-administered drug required for the following:

- Acetaminophen
- Ethinyl estradiol and levonorgestrel
- Metformin
- Simvastatin
- Warfarin

See Drug Interactions (7.2) for the clinical relevance of the following:

- Digoxin

300 mg QD for 7 days

Table 7: Results from 26-Week Placebo-Controlled Clinical Study with INVOKANA as Monotherapy

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo (N=192)</th>
<th>INVOKANA 100 mg (N=195)</th>
<th>INVOKANA 300 mg (N=197)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>7.97</td>
<td>8.06</td>
<td>8.01</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>0.14</td>
<td>-0.77</td>
<td>-1.03</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-0.91</td>
<td>(-1.09; -0.73)</td>
<td>-1.16†</td>
</tr>
<tr>
<td>Percent of Patients Achieving HbA1C &lt; 7%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>166</td>
<td>172</td>
<td>173</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>8</td>
<td>-27</td>
<td>-35</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-36</td>
<td>(-42; -29)</td>
<td>-43†</td>
</tr>
<tr>
<td>2-hour Postprandial Glucose (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>229</td>
<td>250</td>
<td>254</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>5</td>
<td>-43</td>
<td>-59</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-48</td>
<td>(-59.1; -37.0)</td>
<td>-64†</td>
</tr>
<tr>
<td>Body Weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean in kg)</td>
<td>87.5</td>
<td>85.9</td>
<td>86.9</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-0.6</td>
<td>-2.8</td>
<td>-3.9</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-2.2</td>
<td>(-2.8; -1.6)</td>
<td>-3.3†</td>
</tr>
</tbody>
</table>

‡ AUC for drugs given as a single dose and AUC for drugs given as multiple doses

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity was evaluated in 2-year studies conducted in CD1 mice and Sprague-Dawley rats. Canagliflozin did not increase the incidence of tumors in mice dosed at 10, 30, or 100 mg/kg (less than or equal to 14 times the 300 mg clinical dose in males and females), although there were minor alterations in a number of reproductive parameters (decreased sperm velocity, increased number of abnormal sperm, slightly fewer corpora lutea, fewer implantation sites, and smaller litter sizes) at the highest dosage administered.

14 CLINICAL STUDIES

INVOKANA (canagliflozin) has been studied as monotherapy, in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and sitagliptin, metformin and a thiazolidinedione (i.e., pioglitazone), and in combination with insulin (with or without other antihyperglycemic agents). The efficacy of INVOKANA was compared to a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin), both as add-on combination therapy with metformin and sulfonylurea, and a sulfonylurea (glimipride), both as add-on combination therapy with metformin. INVOKANA was also evaluated in adults 55 to 80 years of age and patients with moderate renal impairment.

In patients with type 2 diabetes, treatment with INVOKANA produced clinically and statistically significant improvements in HbA1C compared to placebo. Reductions in HbA1C were observed across subgroups including age, gender, race, and baseline body mass index (BMI).

14.1 Monotherapy

A total of 584 patients with type 2 diabetes inadequately controlled on diet and exercise participated in a 26-week, double-blind, placebo-controlled study to evaluate the efficacy and safety of INVOKANA. The mean age was 55 years, 44% of patients were men, and the mean baseline eGFR was 87 ml/min/1.73 m². Patients taking other antihyperglycemic agents (N=281) discontinued the agent and underwent an 8-week washout followed by a 2-week, single-blind, placebo run-in period. Patients not taking oral antihyperglycemic agents (N=303) entered the 2-week, single-blind, placebo run-in period directly. After the placebo run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily for 2 weeks.

At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p<0.001 for both doses) compared to placebo. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reduction in fasting plasma glucose (FPG), in improved postprandial glucose (PPG), and in percent body weight reduction compared to placebo (see Table 7). Statistically significant (p<0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were 3.7 mmHg and -5.4 mmHg with INVOKANA 100 mg and 300 mg, respectively.

Table 7: Results from 26-Week Placebo-Controlled Clinical Study with INVOKANA as Monotherapy

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo (N=192)</th>
<th>INVOKANA 100 mg (N=195)</th>
<th>INVOKANA 300 mg (N=197)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>166</td>
<td>172</td>
<td>173</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>8</td>
<td>-27</td>
<td>-35</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-36</td>
<td>(-42; -29)</td>
<td>-43†</td>
</tr>
<tr>
<td>2-hour Postprandial Glucose (mg/dL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean)</td>
<td>229</td>
<td>250</td>
<td>254</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>5</td>
<td>-43</td>
<td>-59</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-48</td>
<td>(-59.1; -37.0)</td>
<td>-64†</td>
</tr>
<tr>
<td>Body Weight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mean in kg)</td>
<td>87.5</td>
<td>85.9</td>
<td>86.9</td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-0.6</td>
<td>-2.8</td>
<td>-3.9</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean)</td>
<td>-2.2</td>
<td>(-2.8; -1.6)</td>
<td>-3.3†</td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation in study prior to glycemic rescue therapy

† Least squares mean adjusted for baseline value and stratification factors

p<0.001

- Drug Interactions (7.2)
14.2 Combination Therapy

Add-on Combination Therapy with Metformin

A total of 1284 patients with type 2 diabetes inadequately controlled on metformin monotherapy (greater than or equal to 2,000 mg/day, or at least 1,500 mg/day if higher dose not tolerated) participated in a 26-week, double-blind, placebo- and active-controlled study to evaluate the efficacy and safety of INVOKANA in combination with metformin. The mean age was 55 years, 47% of patients were men, and the mean baseline eGFR was 99 mL/min/1.73 m². Patients already on the required metformin dose (N=1009) were randomized after completing a 2-week, single-blind, placebo-run-in period. Patients taking less than the required metformin dose or patients on metformin in combination with another antihyperglycemic agent (N=275) were switched to metformin monotherapy (at doses described above) for at least 8 weeks before entering the 2-week, single-blind, placebo-run-in. After the placebo-run-in period, patients were randomized to INVOKANA 100 mg, INVOKANA 300 mg, sitagliptin 100 mg, or placebo, administered once daily as add-on therapy to metformin.

At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C compared to placebo when added to metformin. INVOKANA 100 mg and 300 mg once daily resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reduction in fasting plasma glucose compared to placebo when added to metformin (see Table 8). Statistically significant (p<0.001 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -5.4 mmHg and -6.6 mmHg with INVOKANA 100 mg and 300 mg, respectively.

| Table 8: Results from 26-Week Placebo-Controlled Clinical Study of INVOKANA in Combination with Metformin* |

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Metformin (N=183)</th>
<th>INVOKANA 100 mg + Metformin (N=368)</th>
<th>INVOKANA 300 mg + Metformin (N=367)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>7.96</td>
<td>7.94</td>
</tr>
<tr>
<td></td>
<td>Change from baseline</td>
<td>-0.17 (adjusted mean)</td>
<td>-0.79 (adjusted mean)</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo</td>
<td>-0.62 (95% CI)</td>
<td>-0.77 (95% CI)</td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>30%</td>
<td>46%</td>
<td>58%</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>164</td>
<td>169</td>
</tr>
<tr>
<td></td>
<td>Change from baseline</td>
<td>2 (adjusted mean)</td>
<td>-27 (adjusted mean)</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo</td>
<td>-30 (95% CI)</td>
<td>-40 (95% CI)</td>
</tr>
<tr>
<td>2-hour Postprandial Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>249</td>
<td>258</td>
</tr>
<tr>
<td></td>
<td>Change from baseline</td>
<td>-10 (adjusted mean)</td>
<td>-48 (adjusted mean)</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo</td>
<td>-38 (95% CI)</td>
<td>-47 (95% CI)</td>
</tr>
<tr>
<td>Body Weight</td>
<td>Baseline (mean) in kg</td>
<td>86.7</td>
<td>88.7</td>
</tr>
<tr>
<td></td>
<td>% change from baseline</td>
<td>-1.2 (adjusted mean)</td>
<td>-3.7 (adjusted mean)</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo</td>
<td>-2.5 (95% CI)</td>
<td>-2.9 (95% CI)</td>
</tr>
</tbody>
</table>

* Intent-to-treat population
† Least squares mean adjusted for covariates including baseline value and stratification factor
‡ Adjusted p<0.001 for superiority
§ Adjusted p<0.001 for non-inferiority
¶ Adjusted p<0.05
†† There were 121 patients without week 26 efficacy data. Analyses addressing missing data gave consistent results with the results provided in this table.

INVOKANA Compared to Glimepiride. Both as Add-on Combination With Metformin

A total of 1450 patients with type 2 diabetes inadequately controlled on metformin monotherapy (greater than or equal to 2,000 mg/day, or at least 1,500 mg/day if higher dose not tolerated) participated in a 52-week, double-blind, active-controlled study to evaluate the efficacy and safety of INVOKANA in combination with metformin.

The mean age was 56 years, 52% of patients were men, and the mean baseline eGFR was 97 mL/min/1.73 m². Patients tolerating maximally required metformin dose (N=928) were randomized after completing a 2-week, single-blind, placebo-run-in period. Other patients (N=522) were switched to metformin monotherapy (at doses described above) for at least 10 weeks, blinded, placebo run-in period. Other patients (N=522) were switched to metformin monotherapy (at doses described above) for at least 10 weeks, and then increased to 1000 mg/day. Metformin XR or matching placebo was up-titrated every 2-3 weeks during the next 8 weeks of treatment to a maximum daily dose of 1500 to 2000 mg/day, as tolerated; about 90% of patients reached 2000 mg/day.

At the end of treatment, INVOKANA 100 mg and INVOKANA 300 mg in combination with metformin XR resulted in a statistically significant greater improvement in HbA1C compared to their respective INVOKANA doses (100 mg and 300 mg) alone or metformin XR alone.

| Table 9: Results from 26-Week Active-Controlled Clinical Study of INVOKANA Alone or INVOKANA as Initial Combination Therapy with Metformin* |

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Metformin XR (N=237)</th>
<th>INVOKANA 100 mg + Metformin XR (N=237)</th>
<th>INVOKANA 300 mg + Metformin XR (N=237)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>8.81</td>
<td>8.78</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-1.30</td>
<td>-1.37</td>
</tr>
<tr>
<td></td>
<td>Difference from canagliflozin 100 mg (adjusted mean) (95% CI)</td>
<td>-0.40‡‡ (95% CI: -0.59, -0.21)</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>38%</td>
<td>47%‡‡</td>
<td>51%‡‡</td>
</tr>
</tbody>
</table>
**INVIKANA® (canagliflozin) tablets**

### Table 10: Results from 52-Week Clinical Study Comparing INVIKANA to Glimepiride in Combination with Metformin *

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>INVOKANA 100 mg + Metformin (N=485)</th>
<th>INVOKANA 300 mg + Metformin (N=485)</th>
<th>Glimepiride (titrated) + Metformin (N=482)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>7.78</td>
<td>7.79</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-0.82</td>
<td>-0.83</td>
</tr>
<tr>
<td></td>
<td>Difference from glimepiride (adjusted mean) (95% CI)</td>
<td>-0.01† (-0.11; 0.09)</td>
<td>-0.12‡ (-0.22; -0.02)</td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>54%</td>
<td>60%</td>
<td>56%</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>165</td>
<td>164</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-24</td>
<td>-28</td>
</tr>
<tr>
<td></td>
<td>Difference from glimepiride (adjusted mean) (95% CI)</td>
<td>-6 (-10; -2)</td>
<td>-9 (-13; -5)</td>
</tr>
<tr>
<td>Body Weight</td>
<td>Baseline (mean) in kg</td>
<td>86.8</td>
<td>86.6</td>
</tr>
<tr>
<td></td>
<td>% change from baseline (adjusted mean)</td>
<td>-4.2</td>
<td>-4.7</td>
</tr>
<tr>
<td></td>
<td>Difference from glimepiride (adjusted mean) (95% CI)</td>
<td>-5.2† (-5.7; -4.7)</td>
<td>-5.7† (-6.2; -5.1)</td>
</tr>
</tbody>
</table>

* Intent-to-treatment population using last observation in study prior to glycemic rescue therapy
† Least squares mean adjusted for baseline value and stratification factors
‡ p<0.001

**Add-on Combination Therapy With Metformin and Sulfonylurea**

A total of 127 patients with type 2 diabetes inadequately controlled on sulfonylurea monotherapy participated in an 18-week, double-blind, placebo-controlled sub-study to evaluate the efficacy and safety of INVIKANA in combination with sulfonylurea. The mean age was 65 years, 57% of patients were men, and the mean baseline eGFR was 69 mL/min/1.73 m². Patients treated with sulfonylurea monotherapy on a stable protocol-specified dose (greater than or equal to near-maximal dose) for at least 10 weeks completed a 2-week, single-blind, placebo run-in period. After the run-in period, patients with inadequate glycemic control were randomized to INVIKANA 100 mg, INVIKANA 300 mg, or placebo, administered once daily as add-on to sulfonylurea.

As shown in Table 11, at the end of treatment, INVIKANA 100 mg and 300 mg once daily provided statistically significant (p<0.001) improvements in HbA1C relative to placebo when added to sulfonylurea. INVIKANA 300 mg once daily provided statistically significant (p<0.001 for both doses) greater reductions in fasting plasma glucose (-36 mg/dL vs +12 mg/dL), and greater percent body weight reduction (-2.0% vs -0.2%).

---

### Table 11: Results from 18-Week Placebo-Controlled Clinical Study of INVIKANA in Combination with Sulfonylurea *

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Sulfonylurea (N=45)</th>
<th>INVIKANA 100 mg + Sulfonylurea (N=42)</th>
<th>INVIKANA 300 mg + Sulfonylurea (N=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>8.49</td>
<td>8.29</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>0.04</td>
<td>-0.70</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-0.74‡ (-1.15; -0.33)</td>
<td>-0.83‡ (-1.24; -0.41)</td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>18%</td>
<td>43%</td>
<td>57%</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>170</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-0.13</td>
<td>-0.85</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-0.71† (-0.90; -0.52)</td>
<td>-0.92‡ (-1.11; -0.73)</td>
</tr>
<tr>
<td>Body Weight</td>
<td>Baseline (mean) in kg</td>
<td>90.8</td>
<td>93.5</td>
</tr>
<tr>
<td></td>
<td>% change from baseline (adjusted mean)</td>
<td>-0.7</td>
<td>-2.1</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-1.4† (-2.1; -0.7)</td>
<td>-2.0‡ (-2.7; -1.3)</td>
</tr>
</tbody>
</table>

* Intent-to-treatment population using last observation in study prior to glycemic rescue therapy
† Least squares mean adjusted for baseline value and stratification factors
‡ p<0.001

---

*INVOKANA® (canagliflozin) tablets*
INVOKANA® (canagliflozin) tablets

Add-on Combination Therapy With Metformin and Sitagliptin

A total of 217 patients with type 2 diabetes inadequately controlled on the combination of metformin (greater than or equal to 1,500 mg/day) and sitagliptin 100 mg/day (or equivalent fixed-dose combination) participated in a 26-week, double-blind, placebo-controlled study to evaluate the efficacy and safety of INVOKANA in combination with metformin and sitagliptin. The mean age was 57 years, 58% of patients were men, 73% of patients were Caucasian, 15% were Asian, and 12% were Black or African-American. The mean baseline eGFR was 90 mL/min/1.73 m² and the mean baseline BMI was 32 kg/m². The mean duration of diabetes was 10 years. Eligible patients entered a 2-week, single-blind, placebo run-in period and were subsequently randomized to INVOKANA 100 mg or placebo, administered once daily as add-on to metformin and sitagliptin. Patients with a baseline eGFR of 70 mL/min/1.73 m² or greater who were tolerating INVOKANA 100 mg and who required additional glycemic control (fasting finger stick 100 mg/dL or greater at least twice within 2 weeks) were up-titrated to INVOKANA 300 mg. While up-titration occurred as early as Week 4, most (90%) patients randomized to INVOKANA were up-titrated to INVOKANA 300 mg by 6 to 8 weeks.

At the end of 26 weeks, INVOKANA resulted in a statistically significant improvement in HbA1C (p<0.001) compared to placebo when added to metformin and sitagliptin.

Table 13: Results from 26-Week Placebo-Controlled Clinical Study of INVOKANA in Combination with Metformin and Sitagliptin

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Metformin and Sitagliptin (N=108*)</th>
<th>INVOKANA + Metformin and Sitagliptin (N=109*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>8.40</td>
<td>8.50</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-0.03</td>
<td>-0.83</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-0.81 ([-1.11; -0.51])</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%†</td>
<td>9</td>
<td>28</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)§</td>
<td>180</td>
<td>185</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-3</td>
<td>-28</td>
</tr>
<tr>
<td>Difference from placebo (adjusted mean) (95% CI)</td>
<td>-25 ([-39; -11])</td>
<td></td>
</tr>
</tbody>
</table>

* To preserve the integrity of randomization, all randomized patients were included in the analysis. The patient who was randomized once to each arm was analyzed on INVOKANA.
† Early treatment discontinuation before week 26, occurred in 11.0% and 24.1% of INVOKANA and placebo patients, respectively.
§ Patients without week 26 efficacy data were considered as non-responders when estimating the proportion achieving HbA1c < 7%.

As shown in Table 14 and Figure 2, at the end of treatment, INVOKANA 300 mg provided greater HbA1C reduction compared to sitagliptin 100 mg when added to metformin and sulfonylurea (p<0.05). INVOKANA 300 mg resulted in a mean percent change in body weight from baseline of -2.5% compared to +0.3% with sitagliptin 100 mg. A mean change in systolic blood pressure from baseline of -5.06 mmHg was observed with INVOKANA 300 mg compared to +0.95 mmHg with sitagliptin 100 mg.

Table 14: Results from 52-Week Clinical Study Comparing INVOKANA to Sitagliptin in Combination with Metformin and Sulfonlyurea*

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>INVOKANA 300 mg + Metformin and Sulfonlyurea (N=377)</th>
<th>Sitagliptin 100 mg + Metformin and Sulfonlyurea (N=378)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>8.12</td>
<td>8.13</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-1.03</td>
<td>-0.66</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)</td>
<td>-0.37 ([-0.50; -0.25])</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%†</td>
<td>48</td>
<td>35</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>170</td>
<td>164</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-30</td>
<td>-6</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)</td>
<td>-24 (-30; -18)</td>
<td></td>
</tr>
<tr>
<td>Body Weight</td>
<td>87.6</td>
<td>89.6</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-2.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)†</td>
<td>-2.8 ([-3.3; -2.2])</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation in study prior to glycemic rescue therapy
† Least squares mean adjusted for baseline value and stratification factors

INVOKANA® (canagliflozin) tablets

Add-on Combination Therapy With Metformin and Pioglitazone

A total of 342 patients with type 2 diabetes inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and pioglitazone (near-maximal or maximal effective dose) participated in a 26-week, double-blind, active-controlled study to compare the efficacy and safety of INVOKANA 100 mg and who required additional glycemic control (fasting finger stick 100 mg/dL or greater at least twice within 2 weeks) were up-titrated to INVOKANA 300 mg. While up-titration occurred as early as Week 4, most (90%) patients randomized to INVOKANA were up-titrated to INVOKANA 300 mg by 6 to 8 weeks.

At the end of 26 weeks, INVOKANA resulted in a statistically significant improvement in HbA1C (p<0.001) compared to placebo when added to metformin and pioglitazone.

Table 15: Results from 26-Week Placebo-Controlled Clinical Study of INVOKANA in Combination with Metformin and Pioglitazone

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Metformin and Pioglitazone (N=108*)</th>
<th>INVOKANA + Metformin and Pioglitazone (N=109*)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>8.12</td>
<td>8.13</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-1.03</td>
<td>-0.66</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)†</td>
<td>-0.37 ([-0.50; -0.25])</td>
<td></td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%§</td>
<td>48</td>
<td>35</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)†</td>
<td>170</td>
<td>164</td>
</tr>
<tr>
<td>Change from baseline (adjusted mean)</td>
<td>-30</td>
<td>-6</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)</td>
<td>-24 (-30; -18)</td>
<td></td>
</tr>
<tr>
<td>% change from baseline (adjusted mean)</td>
<td>-2.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Difference from sitagliptin (adjusted mean) (95% CI)†</td>
<td>-2.8 ([-3.3; -2.2])</td>
<td></td>
</tr>
</tbody>
</table>

* Intent-to-treat population using last observation in study prior to glycemic rescue therapy
† Least squares mean adjusted for baseline value and stratification factors
‡ INVOKANA + metformin + sulfonylurea is considered non-inferior to sitagliptin + metformin + sulfonylurea because the upper limit of this confidence interval is less than the pre-specified non-inferiority margin of < 0.3.
§ p<0.001

INVOKANA Compared to Sitagliptin, Both as Add-on Combination Therapy With Metformin and Sulfonlyurea

A total of 755 patients with type 2 diabetes inadequately controlled on the combination of metformin (greater than or equal to 2,000 mg/day or at least 1,500 mg/day if higher dose not tolerated) and sulfonylurea (near-maximal or maximal effective dose) participated in a 26-week, double-blind, active-controlled study to compare the efficacy and safety of INVOKANA in combination with metformin and sulfonylurea. The mean age was 57 years, 56% of patients were men, and the mean baseline eGFR was 88 mL/min/1.73 m². Patients already on protocol-specified doses of metformin and sulfonylurea (N=716) entered a 2-week, single-blind, placebo run-in period. Other patients (N=339) were required to be on a stable protocol-specified dose of metformin and sulfonylurea for at least 8 weeks before entering the 2-week run-in period. Following the run-in period, patients were randomized to INVOKANA 300 mg or sitagliptin 100 mg as add-on to metformin and sulfonylurea.

Figure 2: Mean HbA1C Change at Each Time Point (Completers) and at Week 52 Using Last Observation Carried Forward (mITT Population)
INVOKANA® (canagliflozin) tablets

At the end of treatment, INVOKANA 100 mg and 300 mg once daily resulted in a statistically significant improvement in HbA1C (p<0.001 for both doses) compared to placebo when added to metformin and pioglitazone. INVOKANA 100 mg and 300 mg once daily also resulted in a greater proportion of patients achieving an HbA1C less than 7%, in significant reduction in fasting plasma glucose (FPG) and in percent body weight reduction compared to placebo when added to metformin and pioglitazone (see Table 15). Statistically significant (p<0.05 for both doses) mean changes from baseline in systolic blood pressure relative to placebo were -4.1 mmHg and -3.5 mmHg with INVOKANA 100 mg and 300 mg, respectively.

Table 15: Results from 26-Week Placebo-Controlled Clinical Study of INVOKANA in Combination with Metformin and Pioglitazone

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Metformin and Pioglitazone (N=115)</th>
<th>INVOKANA 100 mg + Metformin and Pioglitazone (N=112)</th>
<th>INVOKANA 300 mg + Metformin and Pioglitazone (N=114)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>8.00</td>
<td>7.99</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-0.26</td>
<td>-0.89</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (95% CI)†</td>
<td>-0.62† (-0.81; -0.44)</td>
<td>-0.76† (-0.95; -0.58)</td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>Baseline (mean)</td>
<td>33</td>
<td>47†</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>164</td>
<td>169</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>3</td>
<td>-27</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (95% CI)†</td>
<td>-29† (-37; -22)</td>
<td>-36† (-43; -28)</td>
</tr>
<tr>
<td>Body Weight</td>
<td>Baseline (mean in kg)</td>
<td>94.0</td>
<td>94.2</td>
</tr>
<tr>
<td></td>
<td>% change from baseline (adjusted mean)</td>
<td>-0.1</td>
<td>-2.8</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (95% CI)†</td>
<td>-2.7† (-3.6; -1.8)</td>
<td>-3.7† (-4.8; -2.8)</td>
</tr>
</tbody>
</table>

Table 16: Results from 18-Week Placebo-Controlled Clinical Study of INVOKANA in Combination with Insulin ≥ 30 Units/Day (With or Without Other Oral Antihyperglycemic Agents)

<table>
<thead>
<tr>
<th>Efficacy Parameter</th>
<th>Placebo + Insulin (N=565)</th>
<th>INVOKANA 100 mg + Insulin (N=566)</th>
<th>INVOKANA 300 mg + Insulin (N=587)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>Baseline (mean)</td>
<td>8.20</td>
<td>8.33</td>
</tr>
<tr>
<td></td>
<td>Change from baseline (adjusted mean)</td>
<td>-0.63</td>
<td>-0.72</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (95% CI)†</td>
<td>-0.73† (-0.82; -0.65)</td>
<td>-0.73† (-0.82; -0.65)</td>
</tr>
<tr>
<td>Percent of patients achieving HbA1C &lt; 7%</td>
<td>Baseline (mean)</td>
<td>8</td>
<td>20†</td>
</tr>
<tr>
<td>Fasting Plasma Glucose (mg/dL)</td>
<td>Baseline (mean)</td>
<td>169</td>
<td>170</td>
</tr>
<tr>
<td></td>
<td>% change from baseline (adjusted mean)</td>
<td>-1.8</td>
<td>-2.3</td>
</tr>
<tr>
<td></td>
<td>Difference from placebo (95% CI)†</td>
<td>-2.4† (-2.7; -2.1)</td>
<td>-2.4† (-2.7; -2.1)</td>
</tr>
</tbody>
</table>

‡ Least squares mean adjusted for baseline value and stratification factors
* Intent-to-treat population using last observation in study prior to glycemic rescue therapy
† p<0.001

Add-On Combination Therapy With Insulin (With or Without Other Antihyperglycemic Agents)

A total of 1718 patients with type 2 diabetes inadequately controlled on insulin greater than or equal to 30 units/day or in combination with other antihyperglycemic agents participated in an 18-week, double-blind, placebo-controlled sub-study of a cardiovascular study to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment. The mean age was 64 years, 55% of patients were men, and the mean baseline eGFR was 77 mL/min/1.73 m². Patients on basal, bolus, or basal/bolus insulin for at least 30 units/day or in combination with other antihyperglycemic agents participated in an 18-week, double-blind, placebo-controlled sub-study of a cardiovascular study to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment. The mean age was 63 years, 66% of patients were men, and the mean baseline eGFR was 56 mL/min/1.73 m². Patients on basal, bolus, or basal/bolus insulin for at least 30 units/day or in combination with other antihyperglycemic agents participated in an 18-week, double-blind, placebo-controlled sub-study of a cardiovascular study to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment. The mean age was 68 years, 61% of patients were men, and the mean baseline eGFR was 39 mL/min/1.73 m². Patients were randomized to the addition of INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily. At the end of treatment, INVOKANA provided statistically significant improvements from baseline relative to placebo in HbA1C (p<0.001 for both doses) of -0.57% (95% CI: -0.71; -0.44) for INVOKANA 100 mg and -0.70% (95% CI: -0.84; -0.57) for INVOKANA 300 mg. Statistically significant (p<0.001 for both doses) reductions from baseline in fasting plasma glucose (FPG) and body weight were also observed in this study relative to placebo (see Use in Specific Populations [8.5]).

Moderate Renal Impairment

A total of 269 patients with type 2 diabetes and a baseline eGFR of 30 mL/min/1.73 m² to less than 60 mL/min/1.73 m² inadequately controlled on current diabetes treatment participated in a 26-week, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of INVOKANA in combination with current diabetes treatment (diet or antihyperglycemic agent therapy, with 95% of patients on insulin and/or sulfonylureas). The mean age was 68 years, 61% of patients were men, and the mean baseline eGFR was 39 mL/min/1.73 m². Patients were randomized to the addition of INVOKANA 100 mg, INVOKANA 300 mg, or placebo, administered once daily. At the end of treatment, INVOKANA 100 mg and INVOKANA 300 mg daily provided greater reductions in HbA1C relative to placebo (0.30% [95% CI: -0.53; -0.07]) and 0.40% (95% CI: -0.64; -0.17), respectively) (see Warnings and Precautions [5.2], Adverse Reactions [6.1], and Use in Specific Populations [8.6]).
INVOKEKANA® (canagliflozin) tablets

16 HOW SUPPLIED/STORAGE AND HANDLING

INVOKEKANA (canagliflozin) tablets are available in the strengths and packages listed below:

100 mg tablets are yellow, capsule-shaped, film-coated tablets with “CFZ” on one side and “100” on the other side.

NDC 50458-140-30 Bottle of 30
NDC 50458-140-90 Bottle of 90
NDC 50458-140-50 Bottle of 50
NDC 50458-140-10 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)

300 mg tablets are white, capsule-shaped, film-coated tablets with “CFZ” on one side and “300” on the other side.

NDC 50458-141-30 Bottle of 30
NDC 50458-141-90 Bottle of 90
NDC 50458-141-50 Bottle of 50
NDC 50458-141-10 Blister package containing 100 tablets (10 blister cards containing 10 tablets each)

Storage and Handling
Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F).

17 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide).

Instructions
Instruct patients to read the Medication Guide before starting INVOKEKANA (canagliflozin) therapy and to reread it each time the prescription is renewed.

Inform patients of the potential risks and benefits of INVOKEKANA and of alternative modes of therapy. Also inform patients about the importance of adherence to dietary instructions, regular physical activity, periodic blood glucose monitoring and HbA1C testing, recognition and management of hypoglycemia and hyperglycemia, and assessment for diabetes complications. Advise patients to seek medical advice promptly during periods of stress such as fever, trauma, infection, or surgery, as medication requirements may change.

Instruct patients to take INVOKEKANA only as prescribed. If a dose is missed, advise patients to take it as soon as it is remembered unless it is almost time for the next dose, in which case patients should skip the missed dose and take the medicine at the next regularly scheduled time. Advise patients not to take two doses of INVOKEKANA at the same time.

Inform patients that the most common adverse reactions associated with INVOKEKANA are genital mycotic infection, urinary tract infection, and increased urination.

Inform female patients of child bearing age that the use of INVOKEKANA during pregnancy has not been studied in humans, and that INVOKEKANA should only be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Instruct patients to report pregnancies to their physicians as soon as possible.

Inform nursing mothers to discontinue INVOKEKANA or nursing, taking into account the importance of drug to the mother.

Laboratory Tests
Due to its mechanism of action, patients taking INVOKEKANA will test positive for glucose in their urine.

Hypoglycemia
Inform patients that symptomatic hypoglycemia may occur with INVOKEKANA and advise them to contact their doctor if they experience such symptoms [see Warnings and Precautions (5.1)]. Inform patients that dehydration may increase the risk for hypoglycemia, and to have adequate fluid intake.

Ketoadiposis
Inform patients that ketoadiposis is a serious life-threatening condition. Cases of ketoadiposis have been reported during use of INVOKEKANA. Instruct patients to check ketones (when possible) if symptoms consistent with ketoadiposis occur even if blood glucose is not elevated. If symptoms of ketoadiposis (including nausea, vomiting, abdominal pain, tiredness, and labored breathing) occur, instruct patients to discontinue INVOKEKANA and seek medical advice immediately [see Warnings and Precautions (5.2)].

Acute Kidney Injury
Inform patients that acute kidney injury has been reported during use of INVOKEKANA. Advise patients to seek medical advice immediately if they have reduced oral intake (such as due to acute illness or fasting) or increased fluid losses (such as due to vomiting, diarrhea, or excessive heat exposure), as it may be appropriate to temporarily discontinue INVOKEKANA use in those settings [see Warnings and Precautions (5.3)].
What is the most important information I should know about INVOKANA?
INVOKANA can cause important side effects, including:

• **Dehydration.** INVOKANA can cause some people to become dehydrated (the loss of too much body water). Dehydration may cause you to feel dizzy, faint, lightheaded, or weak, especially when you stand up (orthostatic hypotension).
  
  You may be at higher risk of dehydration if you:
  ○ have low blood pressure
  ○ take medicines to lower your blood pressure, including diuretics (water pill)
  ○ are on a low sodium (salt) diet
  ○ have kidney problems
  ○ are 65 years of age or older

  Talk to your doctor about what you can do to prevent dehydration including how much fluid you should drink on a daily basis.

• **Vaginal yeast infection.** Women who take INVOKANA may get vaginal yeast infections. Symptoms of a vaginal yeast infection include:
  ○ vaginal odor
  ○ white or yellowish vaginal discharge (discharge may be lumpy or look like cottage cheese)
  ○ vaginal itching

• **Yeast infection of the penis (balanitis or balanoposthitis).** Men who take INVOKANA may get a yeast infection of the skin around the penis. Certain men who are not circumcised may have swelling of the penis that makes it difficult to pull back the skin around the tip of the penis. Other symptoms of yeast infection of the penis include:
  ○ redness, itching, or swelling of the penis
  ○ foul smelling discharge from the penis
  ○ rash of the penis
  ○ pain in the skin around penis

  Talk to your doctor about what to do if you get symptoms of a yeast infection of the vagina or penis. Your doctor may suggest you use an over-the-counter antifungal medicine. Talk to your doctor right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

What is INVOKANA?

• INVOKANA is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

• INVOKANA is not for people with type 1 diabetes.

• INVOKANA is not for people with diabetic ketoacidosis (increased ketones in blood or urine).

• It is not known if INVOKANA is safe and effective in children under 18 years of age.

Who should not take INVOKANA?

Do not take INVOKANA if you:

• are allergic to canagliflozin or any of the ingredients in INVOKANA. See the end of this Medication Guide for a list of ingredients in INVOKANA. Symptoms of allergic reaction to INVOKANA may include:
  ○ rash
  ○ raised red patches on your skin (hives)
  ○ swelling of the face, lips, mouth, tongue, and throat that may cause difficulty in breathing or swallowing

• have severe kidney problems or are on dialysis.
### What should I tell my doctor before taking INVOKANA?

Before you take INVOKANA, tell your doctor if you:

- have kidney problems.
- have liver problems.
- have a history of urinary tract infections or problems with urination.
- are on a low sodium (salt) diet. Your doctor may change your diet or your dose of INVOKANA.
- are going to have surgery.
- are eating less due to illness, surgery, or a change in your diet.
- have or have had problems with your pancreas, including pancreatitis or surgery on your pancreas.
- drink alcohol very often, or drink a lot of alcohol in the short-term (“binge” drinking).
- have ever had an allergic reaction to INVOKANA.
- have other medical conditions.
- are pregnant or plan to become pregnant. INVOKANA may harm your unborn baby. If you become pregnant while taking INVOKANA, tell your doctor as soon as possible. Talk with your doctor about the best way to control your blood sugar while you are pregnant.
- are breastfeeding or plan to breastfeed. INVOKANA may pass into your breast milk and may harm your baby. Talk with your doctor about the best way to feed your baby if you are taking INVOKANA. Do not breastfeed while taking INVOKANA.

Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.

INVOKANA may affect the way other medicines work, and other medicines may affect how INVOKANA works. Especially tell your doctor if you take:

- diuretics (water pills)
- phenytoin or phenobarbital (used to control seizures)
- digoxin (Lanoxin®)* (used to treat heart problems)
- rifampin (used to treat or prevent tuberculosis)
- ritonavir (Norvir®, Kaletra®)* (used to treat HIV infection)

Ask your doctor or pharmacist for a list of these medicines if you are not sure if your medicine is listed above.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

### How should I take INVOKANA?

- Take INVOKANA by mouth 1 time each day exactly as your doctor tells you to take it.
- Your doctor will tell you how much INVOKANA to take and when to take it. Your doctor may change your dose if needed.
- It is best to take INVOKANA before the first meal of the day.
- Your doctor may tell you to take INVOKANA along with other diabetes medicines. Low blood sugar can happen more often when INVOKANA is taken with certain other diabetes medicines. See “What are the possible side effects of INVOKANA?”
- If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at the next regularly scheduled time. Do not take two doses of INVOKANA at the same time. Talk to your doctor if you have questions about a missed dose.
- If you take too much INVOKANA, call your doctor or go to the nearest hospital emergency room right away.
- When your body is under some types of stress, such as fever, trauma (such as a car accident), infection, or surgery, the amount of diabetes medicine you need may change. Tell your doctor right away if you have any of these conditions and follow your doctor’s instructions.
- Stay on your prescribed diet and exercise program while taking INVOKANA.
- Check your blood sugar as your doctor tells you to.
- INVOKANA will cause your urine to test positive for glucose.
- Your doctor may do certain blood tests before you start INVOKANA and during treatment as needed. Your doctor may change your dose of INVOKANA based on the results of your blood tests.
- Your doctor will check your diabetes with regular blood tests, including your blood sugar levels and your hemoglobin A1C.
What are the possible side effects of INVOKANA?

INVOKANA may cause serious side effects including:

See “What is the most important information I should know about INVOKANA?”

- **Ketoacidosis (increased ketones in your blood or urine).** Ketoacidosis has happened in people who have type 1 diabetes or type 2 diabetes, during treatment with INVOKANA. Ketoacidosis is a serious condition, which may need to be treated in a hospital. Ketoacidosis can happen with INVOKANA even if your blood sugar is less than 250 mg/dL. Stop taking INVOKANA and call your doctor right away if you get any of the following symptoms:
  - nausea
  - tiredness
  - vomiting
  - trouble breathing
  - stomach area (abdominal) pain

  If you get any of these symptoms during treatment with INVOKANA, if possible, check for ketones in your urine, even if your blood sugar is less than 250 mg/dL.

- **Kidney problems.** Sudden kidney injury has happened to people taking INVOKANA. Talk to your doctor right away if you:
  - reduce the amount of food or liquid you drink for example, if you are sick or cannot eat or
  - you start to lose liquids from your body for example, from vomiting, diarrhea or being in the sun too long

- **Low blood sugar (hypoglycemia).** If you take INVOKANA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin, your risk of getting low blood sugar is higher. The dose of your sulfonylurea medicine or insulin may need to be lowered while you take INVOKANA.

  Signs and symptoms of low blood sugar may include:
  - headache
  - drowsiness
  - weakness
  - confusion
  - dizziness
  - irritability
  - hunger
  - fast heartbeat
  - sweating
  - shaking or feeling jittery

- **Serious allergic reaction.** If you have any symptoms of a serious allergic reaction, stop taking INVOKANA and call your doctor right away or go to the nearest hospital emergency room. See “Who should not take INVOKANA?” Your doctor may give you a medicine for your allergic reaction and prescribe a different medicine for your diabetes.

- **Broken bones (fractures).** Bone fractures have been seen in patients taking INVOKANA. Talk to your doctor about factors that may increase your risk of bone fracture.

The most common side effects of INVOKANA include:

- vaginal yeast infections and yeast infections of the penis (See “What is the most important information I should know about INVOKANA?”)
- changes in urination, including urgent need to urinate more often, in larger amounts, or at night

Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of INVOKANA. For more information, ask your doctor or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

You may also report side effects to Janssen Pharmaceuticals, Inc. at 1-800-526-7736.

How should I store INVOKANA?

- Store INVOKANA at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep INVOKANA and all medicines out of the reach of children.
General information about the safe and effective use of INVOKANA.
Medicines are sometimes prescribed for purposes other than those listed in the Medication Guide. Do not use INVOKANA for a condition for which it was not prescribed. Do not give INVOKANA to other people, even if they have the same symptoms you have. It may harm them.

This Medication Guide summarizes the most important information about INVOKANA. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about INVOKANA that is written for healthcare professionals.

For more information about INVOKANA, call 1-800-526-7736 or visit our website at www.invokana.com.

What are the ingredients of INVOKANA?
Active ingredient: canagliflozin
Inactive ingredients: croscarmellose sodium, hydroxypropyl cellulose, lactose anhydrous, magnesium stearate, and microcrystalline cellulose. In addition, the tablet coating contains iron oxide yellow E172 (100 mg tablet only), macrogol/PEG, polyvinyl alcohol, talc, and titanium dioxide.

* The brands listed are trademarks of their respective owners and are not trademarks of Janssen Pharmaceuticals, Inc. Active ingredient made in Belgium. Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560. Manufactured by: Janssen Ortho, LLC, Gurabo, PR 00778 or Janssen Cilag SpA, Latina, Italy. Licensed from Mitsubishi Tanabe Pharma Corporation. © 2013 Janssen Pharmaceutical Companies

This Medication Guide has been approved by the U.S. Food and Drug Administration. Revised 12/2016